Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU's New IVD Regulation: Key Dates And Deadlines To Shape Your Strategy

Executive Summary

With the publication of the EU IVD Regulation in the Official Journal of the European Union, a series of deadlines for implementation and compliance have been set. Here's a timetable of what to expect.

You may also be interested in...



IVD UK Spring Meeting: The Costly But Necessary Route To IVDR Compliance

Second of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: Not all will survive unscathed as the EU IVD Regulation becomes an operational reality.

IVD UK Spring Meeting: Diagnostics Get New Market Access Tools – But At A Price

First of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: The UK IVD companies are soon to get new tools designed to make market access for innovations easier and more predictable. This is welcome news, given the backdrop of Brexit and the costly route to compliance to the new EU IVD Regulation compliance.

EU's New Medical Device Regulation: A Timetable To Kickstart Planning

The EU's Medical Device and IVD Regulations are published in the Official Journal of the European Union, setting a series of deadlines for implementation and compliance. There is a lot to do in a relatively short amount of time. Here's a timetable of what to expect.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel